Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Summit's photorefractive keratectomy (PRK) laser "approvable" in US:

This article was originally published in Clinica

Executive Summary

The US FDA has notified Summit Technology that its excimer laser is approvable for treating photorefractive keratectomy (PRK). When finally approved, the laser system will be used to perform laser vision correction of up to 7 diopters using a 6 mm optical zone. PMA for use of the laser system for phototherapeutic keratectomy was approved in the US earlier this year. It is currently the only company with marketing approval for ophthalmic use of excimer lasers in the US. The day after receiving the approvable letter, Summit filed a registration statement with the US Securities and Exchange Commission for the issue of 2,200,000 shares of common stock.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT093387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel